Drug intelligence / Profile preview

ExPlas

Development stage: Phase 2
Modality: Tissue Cells → Other Cell Types → Cell Therapies
Administration: Intravenous

Overview

ExPlas is an investigational blood product, specifically 'exercised blood plasma', currently being evaluated in a clinical trial for patients with early symptomatic Alzheimer's disease. The treatment involves infusions of ExPlas, with the hypothesis that it may improve cognitive function or slow disease progression by 'thinning out' a 'poor' signaling environment in the blood. The ongoing study is a randomized, double-blinded trial comparing ExPlas to commercial blood plasma (Octaplasma) and saline (placebo).

Other names: exercised plasmaExPlas

Beyond the preview

Go deeper on ExPlas.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ExPlas.

Explore the full profile